Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.London-based cancer drug developer Antisoma has entered into an alliance whereby it will evaluate and have an option to license early-stage anticancer compounds from EcoBiotics, a drug discovery company based in Queensland, Australia.
Subscribe to our email newsletter
Antisoma will choose up to three compounds from the EcoBiotics portfolio to evaluate during the next year. If these evaluations yield positive results, Antisoma will have rights to license up to two of the compounds for development as anticancer drugs on pre-agreed terms.
EcoBiotics has a diverse portfolio of structurally defined and patent-protected molecules derived from tropical rainforest plants. A number of these molecules have already demonstrated anticancer activity in early preclinical assessments. All those evaluated by Antisoma will be small molecules that can be made by chemical synthesis.
“There is a natural synergy between the discovery expertise of EcoBiotics and the development capabilities of Antisoma that provides the opportunity for rapid advancement of molecules that show potential as oncology drugs,” said EcoBiotics CEO, Dr Victoria Gordon.